Cargando…
Deep-Tissue Activation of Photonanomedicines: An Update and Clinical Perspectives
SIMPLE SUMMARY: Photodynamic therapy (PDT) is a light-activated treatment modality, which is being clinically used and further developed for a number of premalignancies, solid tumors, and disseminated cancers. Nanomedicines that facilitate PDT (photonanomedicines, PNMs) have transformed its safety,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032169/ https://www.ncbi.nlm.nih.gov/pubmed/35454910 http://dx.doi.org/10.3390/cancers14082004 |
_version_ | 1784692575221841920 |
---|---|
author | Shah, Nimit Squire, John Guirguis, Mina Saha, Debabrata Hoyt, Kenneth Wang, Ken Kang-Hsin Agarwal, Vijay Obaid, Girgis |
author_facet | Shah, Nimit Squire, John Guirguis, Mina Saha, Debabrata Hoyt, Kenneth Wang, Ken Kang-Hsin Agarwal, Vijay Obaid, Girgis |
author_sort | Shah, Nimit |
collection | PubMed |
description | SIMPLE SUMMARY: Photodynamic therapy (PDT) is a light-activated treatment modality, which is being clinically used and further developed for a number of premalignancies, solid tumors, and disseminated cancers. Nanomedicines that facilitate PDT (photonanomedicines, PNMs) have transformed its safety, efficacy, and capacity for multifunctionality. This review focuses on the state of the art in deep-tissue activation technologies for PNMs and explores how their preclinical use can evolve towards clinical translation by harnessing current clinically available instrumentation. ABSTRACT: With the continued development of nanomaterials over the past two decades, specialized photonanomedicines (light-activable nanomedicines, PNMs) have evolved to become excitable by alternative energy sources that typically penetrate tissue deeper than visible light. These sources include electromagnetic radiation lying outside the visible near-infrared spectrum, high energy particles, and acoustic waves, amongst others. Various direct activation mechanisms have leveraged unique facets of specialized nanomaterials, such as upconversion, scintillation, and radiosensitization, as well as several others, in order to activate PNMs. Other indirect activation mechanisms have leveraged the effect of the interaction of deeply penetrating energy sources with tissue in order to activate proximal PNMs. These indirect mechanisms include sonoluminescence and Cerenkov radiation. Such direct and indirect deep-tissue activation has been explored extensively in the preclinical setting to facilitate deep-tissue anticancer photodynamic therapy (PDT); however, clinical translation of these approaches is yet to be explored. This review provides a summary of the state of the art in deep-tissue excitation of PNMs and explores the translatability of such excitation mechanisms towards their clinical adoption. A special emphasis is placed on how current clinical instrumentation can be repurposed to achieve deep-tissue PDT with the mechanisms discussed in this review, thereby further expediting the translation of these highly promising strategies. |
format | Online Article Text |
id | pubmed-9032169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90321692022-04-23 Deep-Tissue Activation of Photonanomedicines: An Update and Clinical Perspectives Shah, Nimit Squire, John Guirguis, Mina Saha, Debabrata Hoyt, Kenneth Wang, Ken Kang-Hsin Agarwal, Vijay Obaid, Girgis Cancers (Basel) Review SIMPLE SUMMARY: Photodynamic therapy (PDT) is a light-activated treatment modality, which is being clinically used and further developed for a number of premalignancies, solid tumors, and disseminated cancers. Nanomedicines that facilitate PDT (photonanomedicines, PNMs) have transformed its safety, efficacy, and capacity for multifunctionality. This review focuses on the state of the art in deep-tissue activation technologies for PNMs and explores how their preclinical use can evolve towards clinical translation by harnessing current clinically available instrumentation. ABSTRACT: With the continued development of nanomaterials over the past two decades, specialized photonanomedicines (light-activable nanomedicines, PNMs) have evolved to become excitable by alternative energy sources that typically penetrate tissue deeper than visible light. These sources include electromagnetic radiation lying outside the visible near-infrared spectrum, high energy particles, and acoustic waves, amongst others. Various direct activation mechanisms have leveraged unique facets of specialized nanomaterials, such as upconversion, scintillation, and radiosensitization, as well as several others, in order to activate PNMs. Other indirect activation mechanisms have leveraged the effect of the interaction of deeply penetrating energy sources with tissue in order to activate proximal PNMs. These indirect mechanisms include sonoluminescence and Cerenkov radiation. Such direct and indirect deep-tissue activation has been explored extensively in the preclinical setting to facilitate deep-tissue anticancer photodynamic therapy (PDT); however, clinical translation of these approaches is yet to be explored. This review provides a summary of the state of the art in deep-tissue excitation of PNMs and explores the translatability of such excitation mechanisms towards their clinical adoption. A special emphasis is placed on how current clinical instrumentation can be repurposed to achieve deep-tissue PDT with the mechanisms discussed in this review, thereby further expediting the translation of these highly promising strategies. MDPI 2022-04-15 /pmc/articles/PMC9032169/ /pubmed/35454910 http://dx.doi.org/10.3390/cancers14082004 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Shah, Nimit Squire, John Guirguis, Mina Saha, Debabrata Hoyt, Kenneth Wang, Ken Kang-Hsin Agarwal, Vijay Obaid, Girgis Deep-Tissue Activation of Photonanomedicines: An Update and Clinical Perspectives |
title | Deep-Tissue Activation of Photonanomedicines: An Update and Clinical Perspectives |
title_full | Deep-Tissue Activation of Photonanomedicines: An Update and Clinical Perspectives |
title_fullStr | Deep-Tissue Activation of Photonanomedicines: An Update and Clinical Perspectives |
title_full_unstemmed | Deep-Tissue Activation of Photonanomedicines: An Update and Clinical Perspectives |
title_short | Deep-Tissue Activation of Photonanomedicines: An Update and Clinical Perspectives |
title_sort | deep-tissue activation of photonanomedicines: an update and clinical perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032169/ https://www.ncbi.nlm.nih.gov/pubmed/35454910 http://dx.doi.org/10.3390/cancers14082004 |
work_keys_str_mv | AT shahnimit deeptissueactivationofphotonanomedicinesanupdateandclinicalperspectives AT squirejohn deeptissueactivationofphotonanomedicinesanupdateandclinicalperspectives AT guirguismina deeptissueactivationofphotonanomedicinesanupdateandclinicalperspectives AT sahadebabrata deeptissueactivationofphotonanomedicinesanupdateandclinicalperspectives AT hoytkenneth deeptissueactivationofphotonanomedicinesanupdateandclinicalperspectives AT wangkenkanghsin deeptissueactivationofphotonanomedicinesanupdateandclinicalperspectives AT agarwalvijay deeptissueactivationofphotonanomedicinesanupdateandclinicalperspectives AT obaidgirgis deeptissueactivationofphotonanomedicinesanupdateandclinicalperspectives |